Fig. 1: Treatment and treatment timeline of patients. | Leukemia

Fig. 1: Treatment and treatment timeline of patients.

From: Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial

Fig. 1

Depiction of the treatment each patient received and the time on treatment until sampling. Best response indicated per patient. ALE anti-leukemic effect, ATRA all-trans retinoic acid, C cycle, CR complete remission, CRi CR without recovery of platelets or neutrophils, DEC decitabine, Maint maintenance, PD progressive disease, PR partial remission, SD stable disease, VPA valproic acid.

Back to article page